衰弱老年亚洲房颤患者从华法林换用DOAC的韩国全国研究
采用时变暴露分析发现,与继续华法林相比,换用DOAC与大出血、血栓栓塞、净临床结局及全因死亡风险升高相关。结果提示对华法林管理稳定的衰弱老年亚洲房颤患者,常规换用DOAC需谨慎。
要点
- 衰弱老年房颤患者华法林稳定时换用DOAC,大出血风险升高。
- 换用DOAC后血栓栓塞、净临床结局和全因死亡风险均升高。
- 对华法林管理稳定的衰弱老年患者,不建议常规换用DOAC。
核心结论
- 在衰弱老年亚洲房颤患者中,华法林治疗稳定者换用DOAC与不良临床事件风险升高相关。
- 对华法林管理稳定的衰弱老年房颤患者,常规换用DOAC前需要谨慎考虑。
研究设计与样本
- 利用韩国全国医保数据库,纳入2013年1月至2015年8月期间使用华法林、年龄≥75岁、医院衰弱风险评分≥5且无大出血或血栓栓塞事件的房颤患者。
- 采用基于抗凝暴露的时变分析方法评估从华法林换用DOAC的效应。
主要发现
- 与华法林相比,DOAC治疗的大出血风险更高(HR 1.36,95%CI 1.01-1.81)。
- DOAC治疗的血栓栓塞事件风险更高(HR 1.61,95%CI 1.30-2.00)。
- DOAC治疗的净临床结局风险更高(HR 1.58,95%CI 1.29-1.94)。
- DOAC治疗的全因死亡风险更高(HR 1.20,95%CI 1.02-1.42)。
- 各亚组分析中,DOAC治疗相比华法林在所有结局上均呈更高风险趋势。
临床怎么用
- 对华法林管理稳定的衰弱老年亚洲房颤患者,应避免无明确指征的常规换用DOAC。
- 若考虑换用DOAC,需个体化评估出血与血栓栓塞风险,并充分权衡利弊。
局限性
- 本研究基于韩国医保数据库的观察性分析,DOAC组与华法林组可能存在未测量的混杂因素。
- 研究人群为≥75岁且衰弱评分≥5的亚洲患者,结果向其他人群的外推性有限。
- DOAC种类、剂量及换用原因在数据库中无法完全明确,可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: A recent European trial found that in frail elderly patients with atrial fibrillation (AF), switching from well-managed warfarin to direct oral anticoagulants (DOACs) was associated with higher bleeding risk. This study aimed to evaluate the safety and effectiveness of switching from warfarin to DOACs in frail elderly Asian AF patients. METHODS: The Korean national claims database was used to identify AF patients aged ≥75 years who were prescribed warfarin between January 2013 and August 2015, had Hospital Frailty Risk Score ≥ 5, and experienced no major bleeding or thromboembolic events during this period. To evaluate the effect of switching from warfarin to a DOAC, a time-varying approach based on anticoagulant exposure was applied. The primary outcome was major bleeding. Secondary outcomes included thromboembolic events, net clinical outcome (NCO; composite of major bleeding and thromboembolic events), and all-cause death. RESULTS: Among 12 461 patients, 9112 patients remained on warfarin, whereas 3349 switched to DOACs at least once. During a total follow-up of 11 842 person-years, DOAC treatment was associated with higher risks of major bleeding (hazard ratio 1.36, 95% confidence interval 1.01-1.81), thromboembolic events (1.61, 1.30-2.00), NCO (1.58, 1.29-1.94), and all-cause death (1.20, 1.02-1.42). In various subgroup analyses, DOAC treatment tended to show higher risks of all outcomes compared with warfarin treatment. CONCLUSIONS: In frail elderly Asian AF patients stably maintained on warfarin, switching to DOACs was associated with higher risks of adverse clinical events, suggesting the need for careful consideration before routine switching.
引用
- Lee, Go, Choi, et al. Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study. Eur Heart J. 2026. PMID: 41758696. doi:10.1093/eurheartj/ehaf999
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。